Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 vs. 51.7%), and metformin plus lifestyle was intermediate. Herein we describe the temporal changes in measures of β-cell function and insulin sensitivity over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: TODAY participants (699) were tested periodically with an oral glucose tolerance test to determine insulin sensitivity (1/fasting insulin [1/IF]), insulinogenic index (△I30/△G30) or C-peptide index (△C30/△G30), and β-cell function relative to insulin sensitivity (oral disposition index [oDI]). RESULTS: During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY. Irrespective of treatment, those who failed to maintain glycemic control had significantly lower β-cell function (∼50%), higher fasting glucose concentration, and higher HbA1c at randomization compared with those who did not fail. CONCLUSIONS: The beneficial change in insulin sensitivity and the resultant lower burden on β-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial β-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve β-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures of insulin sensitivity (1/IF) (A), insulinogenic index (△I30/△G30) (B), and oDI ([1/IF] × [△C30/△G30]) (C) in the three treatment groups over 48 months of follow-up in TODAY, analyzed using log-transformed values. The P value refers to the overall effect of treatment group assignment in the longitudinal models for the various parameters under question within the groups.](https://figures.cochat.ai/paper-figures/be1b067684cd4881bcf619e3acd41518/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-1.jpg)
![Figure 2 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures by treatment failure with the three treatment groups combined, analyzed using log-transformed values. A: Insulin sensitivity (1/IF). B: Insulinogenic index (△I30/△G30). C: oDI ([1/IF] × [△C30/△G30]). The P value refers to the overall effect of failed vs. not failed group assignment in the longitudinal models for the various parameters under question within the two groups.](https://figures.cochat.ai/paper-figures/20b5098a6cb74952b4dc2dac4d181449/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Affected young people have a more rapid deterioration in blood glucose levels, an attenuated response to diabetes medication, and more rapid development of diabetes complications (269 -273).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [272]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A 20-35 % decline in beta cell function annually in 10-19 year olds has been reported compared to the ~7% loss in older individuals with T2DM 23 .”
From Type 2 diabetes in adolescents and young adults (2018) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Once treated with metformin after progressing to T2D, youth show a greater rate of treatment failure than adults ( 52 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [52]
In the citing paper
“Early-onset T2DM is also associated with a more aggressive disease phenotype than later-onset T2DM, characterized by a faster β-cell decline (4), higher glycated hemoglobin (HbA1C), higher body mass index (BMI), a more adverse cardiometabolic risk factor profile (5), earlier insulin dependence (6) and a greater risk of both microvascular and macrovascular complications (4).”
From Living with early-onset type 2 diabetes in young adulthood: a narrative review of lived experience and implications for developmentally appropriate care (2026) · cites this paper as [4]
In the citing paper
“β-Cell dysfunction is associated with impaired glycemic control and a greater likelihood of treatment failure in both younger and older adults with T2DM [43,46].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [43]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
TODAY Study Group (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109333 · Cited by 971
Self-citationThe Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Copeland, K. C., Zeitler, P., Geffner, M., Guandalini, C., Higgins, J., Hirst, K., Kaufman, F. R., Linder, B., Marcovina, S., McGuigan, P., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1642 · Cited by 464
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392 · cited 1×
“Even though metformin was effective in the short-term over 16 weeks (2), it remained unknown whether this effect was durable until the results of the TODAY (Treatment Options for type 2 Diabetes in Adolescents andYouth) trial showed.”
BackgroundThe TODAY Study Group (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00237.x · Cited by 260
Self-citationKahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249 · cited 5×
“The ADOPT (A Diabetes Outcome Progression Trial) study of drugnaive adults with type 2 diabetes showed that the insulinogenic index declined at a rate of ;7–11% per year (12).”
BackgroundMethodResultInfluentialHyperinsulinemia in African-American Children
Arslanian, S. A., Saad, R., Lewy, V., Danadian, K., & Janosky, J. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3014 · Cited by 236 · cited 1×
“In addition, differences in insulin clearance in different racial groups (21,22) could confound the insulinogenic index data.”
BackgroundThe Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 207 · cited 1×
“However, TODAY was designed and initiated prior to the discovery of the adverse effects of rosiglitazone (26).”
BackgroundGungor, N., Bacha, F., Saad, R., Janosky, J., & Arslanian, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.638 · Cited by 186
Cited by
Items 201–288 of 288
Seol, R., & Chun, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416600 · Cited by 10
Wheeler, M. D., Pérez, M. B., Lo, F.-S., Liang, B., Lunsford, A., Thórisdóttir, Ó., & Zuckerman‐Levin, N. (2018) · European Journal of Pediatrics · doi:10.1007/s00431-018-3205-z · Cited by 6
Arslanian, S. A., ghormli, L. K. E., Haymond, M., Chan, C. L., Chernausek, S. D., Gandica, R., Gubitosi‐Klug, R., Levitsky, L. L., Siska, M., Willi, S. M., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12998 · Cited by 7
“Although mathematically possible, such values were judged biologically implausible and were treated as missing values similar to our approach in prior TODAY publications.(24,26) Data are presented in mean and SD or percentage.”
BackgroundMethodResultInfluentialWolf, R. M., Cheng, P., Gal, R. L., Beaulieu, L. C., Kollman, C., ISGANAITIS, E. M., Magge, S. N., Mastrandrea, L. D., KLINGENSMITH, G. J., Tamborlane, W. V., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13325 · Cited by 6
“Haller, MD (I); Desmond Schatz, MD (I); Kristin Dayton, MD (I); Janey Adams (C); Shannon Burcham (C); Rebeccah Mercado (C); Megan Smith (C); (7) Yale University, New Haven, CT: William V.”
BackgroundInfant-juvenile type 2 diabetes
Bernal, M., & Aguilar, J. M. V. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2018.03.015 · Cited by 5
Impaired Glucose Tolerance and Altered Body Composition in Obese Young Adults: A Case–Control Study
Mohamed-Mohamed, H., Pardo-Moreno, T., Jiménez-Palomares, M., Ardanaz, B. P., Sanchez-Lara, E., Vázquez-Lara, M. D., de la Mata, M., García‐Morales, V., & Ramos‐Rodríguez, J. J. (2025) · Biomedicines · doi:10.3390/biomedicines13071569 · Cited by 7
“Prolonged exposure to hyperglycemia increases the overall disease burden and hastens the onset of microvascular and macrovascular complications [5,9,10].”
Shao, B., Hou, S., Chan, Y., Shao, C., & Lao, L. (2020) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2020.10.005 · Cited by 7
Fornari, E., Barbetti, F., Iafusco, D., Lombardo, F., GIUDICE, E. M. D., Rabbone, I., & Mozzillo, E. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06530-7 · Cited by 7
Adolescent Immigration and Type-2 Diabetes
Omer, M., Balmakov, Y., Gelman, S., & Twig, G. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01420-5 · Cited by 5
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes
SHAH, A. S., Sadayappan, S., & Urbina, E. M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00989-w · Cited by 8
Type 2 diabetes in youth: Rationale for use of off‐label antidiabetic agents
Kelsey, M. M., Zeitler, P. S., Nadeau, K. J., & SHAH, A. S. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13350 · Cited by 7
Quantitative Extrapolation: An Approach to Validation of Adult Drug Efficacy in Pediatric Subjects
Leil, T. A., Zee, P., Suryawanshi, S., Male, C., & Portman, R. J. (2013) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479013500286 · Cited by 6
Wang, B., Mak, I. L., Liu, K., Choi, E. P. H., Lam, C. L. K., & Wan, E. Y. F. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101607 · Cited by 4
Kim, J. Y., Lee, J., Kim, S. G., & Kim, N. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0601 · Cited by 5
“The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study showed a profound 12% to 25% annual decline in DIo in youths aged 10 to 17 years [32].”
Systemic and ocular outcomes in patients with young-onset type 2 diabetes
Au, A. C., Bajar, B. T., Wong, B. M., Daskivich, L. P., Hosseini, H., & Prasad, P. S. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108670 · Cited by 5
Li, G., Chen, X., Liang, X., Hu, L., Zhang, L., Xu, X., Wu, W., Huang, K., Dong, G., Zhang, J., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12905 · Cited by 4
“The oral disposition index (oDI), representing β-cell function taking into account degree of IS, was calculated as (MI) × ΔI30/ ΔG30.(30,31)”
MethodKim, J. Y., Tfayli, H. M., Bacha, F. F., Lee, S., Gebara, N. Y., & Arslanian, S. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154346 · Cited by 4
“, persistent elevation in HbA1c ≥8% for 6 months or inability to be weaned off insulin) [14].”
BackgroundInfluentialWang, Y., Chin, W. Y., Lam, C. L. K., & Wan, E. Y. F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15856 · Cited by 6
Nadeau, K. J., Arslanian, S. A., Bacha, F. F., Caprio, S., Chao, L. C., Farrell, R. M., Hughan, K. S., Rayas, M. S., Tung, M., Cross, K., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06327-w · Cited by 7
“In support of this, we previously reported both higher insulin sensitivity [33, 34] and an increase in DXA-assessed SAT mass [18] in the metformin+rosiglitazone group in TODAY, and higher ALT and AST concentrations, which are surrogate markers for hepatic steatosis, correlated with lower IC in the…”
Liu, C., Xiang, G., Liang, D., Zhao, X., Xiao, K., & Xie, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-88132-y · Cited by 7
Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities
Dinh, J., Hosey, C. M., & Jones, B. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-019-00375-1 · Cited by 6
Screening for diabetes in asymptomatic children: A simple and efficient method
Wu, W.-C., Li, H., Chiang, C.-C., Sung, F., Wei, J., & Chuang, L. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.09.013 · Cited by 4
Hosey, C. M., Halpin, K. L., Shakhnovich, V., Bi, C., Sweeney, B. R., Yan, Y., & Leeder, J. S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13207 · Cited by 3
Lee, C. J., Bergman, B. K., Gou, R. Y., WILLIAMSON, S. E., & Boye, K. S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01788-7 · Cited by 7
Holman, N., OʼKeefe, J., Gregg, E. W., Tan, G. D., Khunti, K., Valabhji, J., Bakhai, C., Hambling, C. E., Young, B., & Misra, S. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101764 · Cited by 3
“Early-onset disease progresses more aggressively, 38,39 carries higher complication rates, 4,6 and creates a substantial long-term healthcare burden.”
A Systematic Review of Behavioral Interventions on Children at Risk for Diabetes
Alvarado, A. V., Burns, K. F., Katz, S. E., & Robson, S. M. (2023) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2023.01.021 · Cited by 4
Kar, D., Byng, R., Sheikh, A., Nath, M., Zabeen, B., Kar, S., Banu, S., Sarker, M. H. R., Khan, N., Acharjee, D., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04090-7 · Cited by 5
“In adult-onset T2DM, the annual rate of pancreatic β-cell decline is approximately 7% [33, 34], while in young-onset T2DM, it is between 20 and 35% [35, 36].”
REDONDO, M. J., WARNOCK, M. V., Libman, I. M., Bocchino, L. E., Cuthbertson, D. D., Geyer, S. M., Pugliese, A., Steck, A. K., Evans‐Molina, C., Becker, D. J., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0531 · Cited by 3
Self-citationScreening and diagnosis of diabetes in children and pregnant women
Li, H., Wei, J., Chuang, L., Wu, E., & Lee, C. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(14)70731-4 · Cited by 3
Diabetes and Obesity in the Child and Adolescent: Guidelines and Challenges
Cuda, S. E., & Censani, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_40 · Cited by 4
Gaddas, M., Latiri, I., Kebaïli, R., Kacem, I., Jaballah, N., Maatoug, J., Salaani, M., Boughammoura, L., & Saad, H. B. (2022) · Libyan Journal of Medicine · doi:10.1080/19932820.2022.2059896 · Cited by 4
Clinical Manifestations of Insulin Resistance in Youth
Chen, M. E., & Hannon, T. S. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-25057-7_1 · Cited by 6
Pang, G. S.-W., Chung, T. W.-H., Choy, H. H.-T., Lee, C.-Y., Tung, J. Y., Fu, A. C., Tsang, J. W., Yau, H., Belaramani, K. M., Wong, L., et al. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0295 · Cited by 2
Singhal, A., Saxena, D., Ashwini, G., Ahada, R. S., Kurian, N. M., Singh, A. P., Garg, N., Bhatia, E., & Yadav, S. (2025) · Endocrine Connections · doi:10.1530/ec-25-0226 · Cited by 5
Youth-onset type 2 diabetes: Advances, treatments, and challenges in prevention
Sparling, D. P., & Tryggestad, J. B. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.020 · Cited by 3
Kar, D., Molokhia, M., Wierzbicki, A. S., Koziell, A. B., Byng, R., Spicer, S. G., Farina, N., Pinkney, J. H., Song, S. H., Zabeen, B., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-24521-7 · Cited by 3
Youth-onset type 2 diabetes mellitus—a distinct entity?
Madhu, S. V. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00993-x · Cited by 2
“TODAY study showed a 20–35% annual decline in β-cell function in adolescents aged 10–19 years with type 2 as compared to a 7% decline in older individuals with type 2 diabetes [11].”
Hao, Z., Yao, J., Zhao, X., Liu, R., Chang, B., & Shao, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-41883-y · Cited by 3
Advancements in pharmacotherapy options for treating diabetes in children and adolescents
Daniali, M., Nikfar, S., & Abdollahi, M. R. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2290491 · Cited by 3
“We found a multicenter randomized controlled trial that compared metformin (1 g/day) with rosiglitazone (4 mg/day) or placebo in 699 children with T2D aged 10 to 17 years [41].”
BackgroundKatz, L. E. L., Gidding, S. S., Otvos, J. D., Drews, K. L., Bacha, F. F., Willi, S. M., Marcovina, S., McKay, S. V., & Weinstock, R. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.01.005 · Cited by 2
Diabetes Care to Date: “The Hits Just Keep on Coming!”
Cefalu, W. T. (2013) · Diabetes Care · doi:10.2337/dc13-0906 · Cited by 2
Young-onset type 2 diabetes: no room for complacency
Song, S. H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70147-0 · Cited by 2
Understanding Type 2 Diabetes in Students With Obesity and the Role of the School Nurse
Berquist, M. J. (2015) · NASN School Nurse · doi:10.1177/1942602x15571368 · Cited by 4
Hao, S., Cossen, K., Westbrook, A. L., Umpierrez, G. E., & Vellanki, P. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.07.002 · Cited by 2
Krnić, N., Šeša, V., Mrzljak, A., & Berković, M. C. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.623 · Cited by 2
Bremer, A. A., & Arreaza-Rubín, G. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818823770 · Cited by 2
Pharmacotherapy of Children and Adolescents with Type 2 Diabetes Mellitus
Kapellen, T. M. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_266 · Cited by 3
Kanatsuka, A., Sato, Y., Higashi, Y., Goto, Y., Kawai, K., Maegawa, H., & Japan Diabetes Data Management Study Group (JDDM) (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13558 · Cited by 1
Rosiglitazone maleate increases weight gain and body fat content in growing lambs
Fahri, F. T., Clarke, I. J., Pethick, D. W., Warner, R. D., & Dunshea, F. R. (2015) · Animal Production Science · doi:10.1071/an14885 · Cited by 1
Turer, C. B., Park, J. J., Gupta, O. T., Ramirez, C. M., Basit, M. A., Heitjan, D. F., & Barlow, S. E. (2023) · Pediatric Obesity · doi:10.1111/ijpo.13066 · Cited by 1
Kitamura, A., Kurajoh, M., Miki, Y., Kakutani, Y., Yamazaki, Y., Ochi, A., Morioka, T., Mori, K., Shoji, T., & Emoto, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14279 · Cited by 4
Lee, D.-H., Jeon, H. J., & Oh, T. K. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e77 · Cited by 1
Nature vs nurture of glucose homeostasis trajectories in children from the ALSPAC study
Gamache, I., Fagbemi, K., Harnois‐Leblanc, S., Greenwood, C. M. T., Henderson, M., Hulst, A. V., Timpson, N. J., & Manousaki, D. (2026) · Diabetologia · doi:10.1007/s00125-026-06722-5 · Cited by 1
Sharma, A. R., Lázaro-Guevara, J. M., STUCKI, D., Anand, S., Welt, C. K., & Pezzolesi, M. G. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag100
“…are prevalent in young adults with T2D likely due worse glycemic control and obesity [10, 29, 30], which further amplifies the decline in β -cell function. β -cell function studies in adolescents with T2D showed lower β -cell reserve and lower insulin sensitivity compared to adults [8, 31].”
20 Things You Didn’t Know About Type 2 Diabetes in Emerging Adults
Cha, E., HAW, J. S., & Faulkner, M. S. (2017) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000385 · Cited by 1
“The research also indicates that the maximum preservation of "-cell function (possibly achieved by healthy lifestyle and weight loss) before significant loss is essential to delay type 2 diabetes progression, attain glycemic goals, and prevent diabetes complications.(9)”
BackgroundType 2 Diabetes and Pre-Diabetes in Pediatric Obesity
Bensignor, M. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_9 · Cited by 1
Chou, Y.-H., Su, Y.-T., Lo, F., Chiu, C.-F., & Huang, Y.-C. (2024) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2023.09.011 · Cited by 2
Özer, Y., & Altınok, E. İ. (2024) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1373905 · Cited by 1
Preserving insulin function in diabetes: a case report
Oota, M. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04714-w · Cited by 1
“With regards to the intake of metformin, based on the findings from the TODAY study [11], it is evident that metformin, when used in combination with other treatments, can sig - nificantly improve insulin sensitivity and β-cell function initially; however, the long-term effectiveness in maintaining…”
BackgroundEffects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting
Barajas, A. G., Gagnon, C. A., & Schmitt, J. A. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70053 · Cited by 1
“In addition, studies have shown high therapeutic failure rates with metformin in those with rapid beta-cell deterioration, with no significant effects on weight [7].”
Pinhas‐Hamiel, O., Zeitler, P. S., & Kelsey, M. M. (2017) · Contemporary Endocrinology · doi:10.1007/978-3-319-68192-4_24
Bariatric Surgery and Adolescent Type 2 Diabetes
SHAH, A. S., & Inge, T. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55138-0.00013-9
Bypass gástrico en el tratamiento de diabetes tipo 2 en la juventud
Maquilón, A. G. C., Olvera, C. D. A., Checa, T. J. M., & Flores, J. S. D. M. (2019) · RECIMUNDO · doi:10.26820/recimundo/3.(3).septiembre.2019.145-162
Typ-2-Diabetes bei Kindern ist für Diabetologen eine harte Nuss
Kapellen, T. M. (2019) · Pädiatrie · doi:10.1007/s15014-019-1500-4
Techniques to Assess Insulin Action in Youth
Michaliszyn, S. F., & Arslanian, S. A. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-25057-7_2
Effect of Metformin Intervention on Pancreatic β-Cell Apoptosis
Xie, D., Gao, Z., Liu, M., & Wang, D. (2022) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2022.3013
(2020) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610023610-33
배, 재. (2022) · Public Health Weekly Report · doi:10.56786/phwr.2022.15.35.2474
Hao, Z., Yao, J., Zhao, X., Liu, R., Chang, B., & Shao, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3089588/v1
Metformin Can Attenuate Beta-Cell Hypersecretion—Implications for Treatment of Children with Obesity
Wen, Q., Stenlid, R., Chowdhury, A. I., Ciba, I., Aydın, B. K., Cerenius, S. Y., Manell, H., Forslund, A. H., & Bergsten, P. (2023) · Metabolites · doi:10.3390/metabo13080917
(2020) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610024181-33
Wu, X., Wang, R., Chen, J., Feng, G., Wang, X., Bai, R. N., Liang, X., Cao, B., Gong, C., Li, W., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14194 · Cited by 1
Management of Early-Onset Type 2 Diabetes
Kim, J. H. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.1.4
Bacha, F. F. (2024) · Diabetes Care · doi:10.2337/dci24-0006
Kar, D., Byng, R., Spicer, S. G., Farina, N., Pinkney, J. H., Song, S. H., Zabeen, B., Kar, S., Jonnagaddala, J., Liaw, S., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5951257/v1
Sangande, F., Ningsih, S. S., Agustini, K., Kusumastuti, S. A., Nuralih, N., Fajriawan, A. A., Chandra, M., Rosmalawati, S., Asnawi, A., & Budipramana, K. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2499224 · Cited by 2
“For instance, a combination of rosiglitazone with metformin resulted in better IR improvement than metformin alone (Arslanian et al., 2013), demonstrating the important role of multi-target therapy in IR treatment.”
Avramovic, S., Li, X., Enquobahrie, D. A., Schwartz, M. D., Korpak, A. M., Boyko, E. J., & Wander, P. L. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112332
Karakaya, A. A., Yıldırım, R., Trabzon, G., Özbek, M. N., & Orhan, Ö. (2025) · Pamukkale Medical Journal · doi:10.31362/patd.1535798
Lynam, K., & O'Grady, M. J. (2025) · Pediatric Diabetes · doi:10.1155/pedi/8892271
“…increase was of particular concern given that youth-onset type 2 diabetes is ostensibly a more aggressive disease with more rapid beta-cell loss [18] and more rapid progression towards microvascular complications compared to childhood-onset type 1 diabetes [19] or type 2 diabetes with onset in…”
Early Versus Late Diagnosis of Youth‐Onset Type 2 Diabetes
Krishnan, N., Crimmins, N. A., Swertfeger, D. K., SCHAAF, L. R., & SHAH, A. S. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70116
Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use
Arslanian, S. A., Barrett, T. G., & Shehadeh, N. (2026) · Pediatric Diabetes · doi:10.1155/pedi/4555805
DeLacey, S. E., Chen, W., Ranganna, A., Feng, S., Fishbein, M. H., & Bianco, M. E. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70211
Yu, P., Sun, M., Wang, H., Wang, J., Zheng, S., Zhang, H., & 王中京 (2026) · European journal of medical research · doi:10.1186/s40001-026-04493-8
丁, 伟. (2025) · 健康文摘 · doi:10.61654/zzjkwz0341
Seminars in pediatric sugery pediatric metabolic and bariatric surgery
Egan, C. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151652
Goh, J. S. R., Sim, L. X., Seetho, I. W., Kao, S. L., Chin, R. T., Khoo, C. M., Lim, A. Y. L., & Eng, P. C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903159
Diabetes Mellitus: Review of the Common, Rare, and Uncommon (Conceptual and Metaphorical) Types
Pliszka, M., & Szablewski, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219611
Metadata
- Authors
- TODAY Study Group
- Corresponding author
- TODAY Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-05-15
- Volume
- 36
- Issue
- 6
- Pages
- 1749-1757
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3661836
- OpenAlex
- W59232989
- Cited by
- 288
- References
- 25
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 30 · 2023: 25 · 2022: 37 · 2021: 28 · 2020: 27 · 2019: 16 · 2018: 23 · 2017: 12 · 2016: 12 · 2015: 16 · 2014: 18 · 2013: 8
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000130, UL1TR000005, UL1TR000448, UL1TR000439)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061239, U01DK061212, U01DK061254, U01DK061242, U01DK061230)
- National Center for Research Resources (M01RR000125, UL1RR024989, UL1RR025758, M01RR001066, UL1RR024153, UL1RR024134, M01RR000043, M01‐RR00043‐45, M01RR014467, M01RR000069, UL1RR024992, UL1RR024139, M01RR000084, M01RR000036, UL1RR025780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, rosiglitazone, insulin sensitivity, beta-cell function, oral disposition index, insulinogenic index, treatment failure, beta-cell reserve
- MeSH terms
- Adolescent, Child, Diabetes Mellitus, Type 2, Drug Combinations, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Life Style, Male, Metformin, Thiazoles, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.